2 recruiting, 1 active not recruiting, 1 completed, 1 withdrawn. 1 Not applicable, 1 Phase 1, 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 1 | Recruiting 1 |
| Phase 1 | 1 | Active not recruiting 1 |
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Completed 1 |
Follow Endometrioid Carcinoma: new trials by email Literature Review of Endometrioid Carcinoma trials Research Report on Endometrioid Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer Sintilimab or Pembrolizumab and medroxyprogesterone acetate (MPA)/ megestrol acetate (MA) - Endometrial Cancer, Endometrioid Carcinoma | Not applicable | Recruiting | Peking University People's Hospital | 10 | 2024-09-02 | 2026-08-10 |
| Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer Carboplatin - Ovarian Cancer, Relapsed Ovarian Cancer | Phase 2 | Recruiting | University College, London | 80 | 2023-05-24 | 2024-04-12 |
| Phase I Trial of Defactinib and VS-6766. VS-6766, Defactinib - NSCLC, Low Grade Serous Ovarian Cancer | Phase 1 | Active not recruiting | Institute of Cancer Research, United Kingdom | 87 | 2017-12-12 | 2026-03-10 |
| Evaluation of Sentinel Node Policy in Early Stage Endometrial Carcinomas at Intermediate and High Risk of Recurrence. Pre-operative SN mapping with radionucleide, Intra-operative SN mapping with patent V blue dye, Intra-operative SN mapping with indocyanin green - Non Endometrioid Carcinoma, Endometrioid Carcinoma | Phase 3 | Completed | Centre Oscar Lambret | 262 | 2015-11-19 | 2026-09-15 |
| Endometriosis and Frequency of Endometriosis-associated Ovarian Carcinomas (EAOC) Endometrioid Carcinoma, Clear Cell Carcinoma | Withdrawn | University Hospital, Basel, Switzerland | 2012-10-01 | 2015-04-01 |
Carcinoma, Endometrioid (5) · Adenocarcinoma, Clear Cell (1) · Endometrial Neoplasms (1) · Endometriosis (1) · Fallopian Tube Neoplasms (1) · Ovarian Neoplasms (1) · Pancreatic Neoplasms (1) · Turcot syndrome (1)
Adenocarcinoma (5) · Adnexal Diseases (5) · Carcinoma (5) · Endocrine System Diseases (5) · Female Urogenital Diseases (5) · Female Urogenital Diseases and Pregnancy Complications (5) · Genital Diseases (5) · Genital Diseases, Female (5) · Genital Neoplasms, Female (5) · Gonadal Disorders (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Glandular and Epithelial (5) · Ovarian Diseases (5)
Carboplatin (1) · Hysterectomy (1) · Medroxyprogesterone Acetate (1) · Megestrol Acetate (1) · RO5126766 (1) · defactinib (1) · pembrolizumab (1) · sintilimab (1)
Centre Oscar Lambret (1) · Institute of Cancer Research, United Kingdom (1) · Peking University People's Hospital (1) · University College, London (1) · University Hospital, Basel, Switzerland (1)
United Kingdom (2) · China (1) · France (1)
Ellen C Obermann, MD (1) · Ellen Obermann, MD, Dr. (1) · Jianliu Wang, Professor (1) · Udai Banerji, FRCP, PhD (1)
PMID 34195683, PMID 37598000, PMID 39806715, PMID 40579546
2015 (1), 2017 (1)